An update from Cynata Therapeutics Limited ( (AU:CYP) ) is now available.
Cynata Therapeutics announced promising results from preclinical studies of its Cymerus™ MSCs in treating ischaemic heart disease, the leading global cause of death. The studies revealed that encapsulated Cymerus™ MSCs significantly improved heart function and reduced harmful structural changes in heart tissues in a rat model of heart attack. This novel, minimally invasive delivery method may enhance clinical translation and long-term effects, potentially addressing a critical unmet need in post-heart attack care. The research, supported by a $1 million Australian Government grant, was conducted in collaboration with multiple institutions and has been submitted for peer review.
More about Cynata Therapeutics Limited
Cynata Therapeutics Limited is an Australian clinical-stage biotechnology company specializing in stem cell and regenerative medicine. The company focuses on developing therapies using its proprietary Cymerus™ platform, which utilizes induced pluripotent stem cells (iPSCs) to produce mesenchymal stem cells (MSCs) at a commercial scale without relying on multiple donors. Cynata has demonstrated positive safety and efficacy in various clinical trials for conditions such as graft versus host disease, diabetic foot ulcers, and osteoarthritis.
YTD Price Performance: -27.89%
Average Trading Volume: 1,111
Technical Sentiment Signal: Strong Buy
Current Market Cap: $22.53M
Learn more about CYP stock on TipRanks’ Stock Analysis page.